arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

RAPID MICRO BIOSYSTEMS, INC.

RPID
$0.62 ▼ -0.07 (-9.71%) at close
Industrials ·Laboratory Analytical Instruments ·USLaboratory Analytical Instruments
27 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
16
Health
Poor
Bearish
auto_awesome

Analytical Summary

RAPID MICRO BIOSYSTEMS, INC. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $30.0M
Dividend Yield —
Revenue Growth 10.9% →
Op. Margin -153.0% ↗
ROIC -26.4% ↗
FCF / Share $-0.27 ↗
Trailing P/E —
Price / Book 1.7x
FCF Yield —
Debt / Equity 1.08
info Valuation on last close. End-of-day price, Nov 5, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$8.05M
↑ +10.9% —
Net Income Profit after all expenses
$-14.28M
↓ -26.7% —
Operating Margin Operating profit as % of sales
-153.0%
↑ +11.6% 1th
FCF / Share Free cash flow per share
$-0.27
↓ -18.6% —
Long-Term Debt Long-term obligations
$19.14M
— +0.5% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
2
Returns ↓
5
Financial Health ↓
31
Cash Quality ↓
47

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 7 years · 27 quarters